{"id":53240,"date":"2012-10-02T14:20:59","date_gmt":"2012-10-02T14:20:59","guid":{"rendered":"http:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/uncategorized\/freedom-meditech-secures-2-million-in-funding-from-silicon-valley-bank.php"},"modified":"2012-10-02T14:20:59","modified_gmt":"2012-10-02T14:20:59","slug":"freedom-meditech-secures-2-million-in-funding-from-silicon-valley-bank","status":"publish","type":"post","link":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/freedom\/freedom-meditech-secures-2-million-in-funding-from-silicon-valley-bank.php","title":{"rendered":"Freedom Meditech Secures $2 Million in Funding from Silicon Valley Bank"},"content":{"rendered":"<p><p>    SAN DIEGO--(BUSINESS WIRE)--  <\/p>\n<p>    Freedom Meditech, Inc., developer of non-invasive ophthalmic    products for the detection of disease and management of patient    health, today announced it has secured a $2 million line of    credit from Silicon Valley Bank (SVB). The funds will be used    to ramp up manufacturing and distribution of the company's    ClearPath DS-120 Lens Fluorescence Biomicroscope, currently    under regulatory review in the U.S. and European Union.  <\/p>\n<p>    SVBs due diligence on our ClearPath DS-120 showed a strong    mix of proven technology, market opportunity and just how far    we have come in reducing manufacturing, regulatory and    marketing risk for the product, said Craig Misrach, Chairman    and CEO of Freedom Meditech. The financing provided by SVB is    a springboard to launch this new and exciting product in the    global healthcare marketplace.  <\/p>\n<p>    Terms of the credit facility include an initial disbursement    with additional funds available upon attaining certain    milestones. The transaction is in anticipation of a Series B    financing close by the company.  <\/p>\n<p>    The company plans to launch the ClearPath in international    markets with an initial focus on countries that accept the CE    Mark and CSA Certification Mark. The CE Mark is required to    sell in the 27 countries that comprise the EU and is a gateway    to other non-regulated markets. CSA certification is required    to sell in Canada and is an entre to certain Latin American    markets. The product is also under U.S. Food and Drug    Administration 510(k) review.  <\/p>\n<p>    The ClearPath DS-120 incorporates the use of proprietary    biophotonic spectroscopy to detect autofluorescence of the    crystalline lens of the eye. The ClearPath non-invasively scans    blue light into the lens of the eye in less than six (6)    seconds and produces a result immediately at the point of care.    The test is painless, requires no special preparation such as    fasting, and produces no bio-hazardous waste or disposal cost.    This information, along with other data collected in a routine    health examination, can provide clinicians with a more robust    wellness program designed to identify the potential risk of    chronic systemic disease and the need to institute appropriate    patient management plans.  <\/p>\n<p>    About Freedom Meditech Freedom Meditech, Inc. is a    medical device company focused on the commercialization of    novel ophthalmic technologies for the detection of disease and    management of patient health. The company maintains research    and development operations throughout California and Ohio with    supporting corporate and engineering activities in San Diego,    CA. For more information, visit     <a href=\"http:\/\/www.freedom-meditech.com\" rel=\"nofollow\">http:\/\/www.freedom-meditech.com<\/a>.  <\/p>\n<p>    AboutSilicon Valley BankSilicon Valley    Bankis the premier bank for technology, life science,    cleantech, venture capital, private equity and premium wine    businesses. SVB provides industry knowledge and connections,    financing, treasury management, corporate investment and    international banking services to its clients worldwide through    27 U.S. offices and seven international operations. (SIVB)www.svb.com.    Silicon Valley Bankis theCaliforniabank    subsidiary and the commercial banking operation ofSVB    Financial Group. Banking services are provided bySilicon    Valley Bank, a member of theFDICand    theFederal Reserve System. SVB Financial    Groupis also a member of theFederal Reserve    System.  <\/p>\n<p>    The ClearPath DS-120 is an investigational device and is    limited by federal (U.S.) law to investigational use.  <\/p>\n<p>    ClearPath DS-120 Lens Fluorescence Biomicroscope is a    trademark owned by Freedom Meditech, Inc.  <\/p>\n<\/p>\n<p>Excerpt from:<\/p>\n<p><a target=\"_blank\" href=\"http:\/\/finance.yahoo.com\/news\/freedom-meditech-secures-2-million-150500212.html;_ylt=A2KJjag0.GpQZloAHEv_wgt.\" title=\"Freedom Meditech Secures $2 Million in Funding from Silicon Valley Bank\">Freedom Meditech Secures $2 Million in Funding from Silicon Valley Bank<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p> SAN DIEGO--(BUSINESS WIRE)-- Freedom Meditech, Inc., developer of non-invasive ophthalmic products for the detection of disease and management of patient health, today announced it has secured a $2 million line of credit from Silicon Valley Bank (SVB). The funds will be used to ramp up manufacturing and distribution of the company's ClearPath DS-120 Lens Fluorescence Biomicroscope, currently under regulatory review in the U.S.  <a href=\"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/freedom\/freedom-meditech-secures-2-million-in-funding-from-silicon-valley-bank.php\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"limit_modified_date":"","last_modified_date":"","_lmt_disableupdate":"","_lmt_disable":"","footnotes":""},"categories":[30],"tags":[],"class_list":["post-53240","post","type-post","status-publish","format-standard","hentry","category-freedom"],"modified_by":null,"_links":{"self":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/53240"}],"collection":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/comments?post=53240"}],"version-history":[{"count":0,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/53240\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/media?parent=53240"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/categories?post=53240"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/tags?post=53240"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}